Active pharmaceutical substance of Vildiab is Vildagliptin.
Vildiab is administered if diabetes is not controlled by diet and physical exercises. The drug facilitates the control of blood sugar.
Indications for usage
For type 2 diabetes mellitus in adults as monotherapy (if diet, physical load is not effective, and in case of metformin intolerance); double therapy with metformin, sulfonylurine drugs, thiazolidinedione, as triple therapy with sulfonylurine drugs and metformin if they are not effective.
Advantages of VILDIAB medicine
Complex effect on carbohydrate metabolism (enhancement of insulin secretion by glucose-dependent mechanism, inhibition of glucagon secretion, decreased appetite, suppression of β-cell apoptosis, enhancement of their proliferation, and neo-genesis from precursor cells in pancreas ducts); possible use in monotherapy and in combination, adequate compatibility with other hypoglycemic medicines, friendly use, i.e.1 capsule 50 mg 2 times daily.
On sale starting from July 1,2024.
Contraindications and undesirable reactions. Do not administer in pregnancy and lactation.
READ LEAFLET BEFORE USE